Santen Pharmaceutical Co., Ltd.

Santen develops and sells eye medicines and expands regional portfolios through partnerships for other companies’ products. In the year ended March 2026, Japanese drug-price reductions and generic competition weighed on consolidated revenue, which fell to ¥291.6bn. EMEA growth of 7.8% became 0.4% when currency effects were excluded. Understanding the Chinese distribution agreement and the next year’s growth forecast requires attention to the rights involved, regional pricing conditions, currency and selling costs.